2020
Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease)
Dash B, Peyvandi H, Duan K, Richardson E, Ndon S, Gabrick K, Faz A, Persing J, Dardik A, Hsia H. Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease). Processes 2020, 8: 1408. DOI: 10.3390/pr8111408.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsThromboangiitis obliteransYoung male smokersBuerger's diseaseImmunomodulatory approachesMale smokersSurgical bypassPathological findingsTreatment modalitiesVascular diseaseDefinitive cureLower extremitiesMedium arteriesLesion treatmentTherapeutic modalitiesTAO treatmentTherapeutic angiogenesisCell therapyDiseaseObliteransStem cellsCurrent knowledgeModalitiesTreatmentPotential optionVasculitis
2018
Comparison of therapeutic effects between open surgery and endovascular therapy for juxtarenal aortic occlusion
Gu Y, Qi L, Dardik A, Gao X, Guo L, Tong Z, Guo J, Zhang J, Wang Z. Comparison of therapeutic effects between open surgery and endovascular therapy for juxtarenal aortic occlusion. Vascular Investigation And Therapy 2018, 1: 74-79. DOI: 10.4103/vit.vit_16_18.Peer-Reviewed Original ResearchAbdominal aortic occlusionJuxtarenal aortic occlusionAortic occlusionOpen surgeryEndovascular therapyEndovascular treatmentPatency ratesOpen groupClinical conditionsENDO groupEndovascular therapy groupSymptom improvement rateMore blood lossFaster postoperative recoveryHospital stay timePatient's clinical conditionTechnical success rateArterial bypass surgeryBypass surgeryPostoperative recoverySurgical bypassBlood lossHospitalization expensesMean ageDisease history